上皮性卵巢癌RASSF1A基因甲基化与新辅助化疗疗效的相关性

摘要

Objective To explore the relation between methylation status of RAS association domain family 1A (RASSF1A) in patients with advanced epithelial ovarian cancer and the clinical efficacy of cisplatin based neoadjuvant therapy. Methods Forty patients with advanced epithelial ovarian cancer were selected and the methylation status of RASSF1A was evaluated by methylation specific PCR (MSP). The clinical efficacy was compared between patients with different methylation statuses of RASSF1A. Results The response rate of 15 patients with methylation status in the promoter region was 26.6％ and that of 25 patients without methylation status was 48.0％, with significant difference ( P ＜ 0.05 ). Conclusion The methylation status of RASSF1 A can influence the clinical efficacy of neoadjuvant therapy in patients with advanced epithelial ovarian cancer.%目的:比较Ras相关区域家族1A (Ras association domain family 1A,RASSF1A)基因表达以及甲基化程度在晚期上皮性卵巢癌中是否存在差异,以及该差异与采用TP方案进行的新辅助化疗模式的关系.方法:选取在我院住院上皮性卵巢癌患者40例,采用甲基化特异性PCR技术(MSP)针对RASSF1A启动子区域的甲基化程度进行分析.同时分析不同RASSF1A表达患者的TP方案新辅助化疗临床疗效.结果:40例患者中,15例患者RASSF1A启动子区域发生甲基化,25例患者RASSF1A未发生甲基化.15例发生甲基化患者新辅助化疗有效率为26.6%,未发生甲基化患者有效率为48.0%,2组比较差异有统计学意义(P<0.05).结论:RASSF1A基因启动子区域甲基化程度的差异与晚期上皮性卵巢癌患者新辅助化疗疗效关系密切.